Leading Unlicensed Medicines and Managed Access Program Companies

Twenty companies are covered in the report on this category, and they differ more in what else they do than in what they do for unlicensed medicine and managed access programs.

The broader context of the unlicensed medicines and managed access programs market explains why these companies are grouped by type rather than ranked, since the report does not rank providers and treats every company on a neutral and descriptive basis.

The twenty companies are Clinigen, ICON plc, IQVIA, Parexel, Syneos Health, Inceptua Group, Tanner Pharma Group, EVERSANA, Worldwide Clinical Trials, Alira Health, ProductLife Group, myTomorrows, Marken, PX'Therapeutics Access Services, ClinChoice, PrimeVigilance, Ergomed, Rhenus Life Sciences, PCI Pharma Services and Catalent.

They fall into three groups: companies whose business centres on named patient and managed access programs, clinical research and development service providers that include access programs among their services, and logistics, pharmacovigilance and compliance providers that supply one essential part of a program.

The grouping is useful because a manufacturer's experience of a provider depends heavily on its type. A dedicated specialist and a large research organisation can both run a program, but they bring different strengths and different ways of working.

Clinigen is listed first among the companies covered, and within its group it is described on the same factual basis as the others, with no claim of superiority on performance, reach or quality.

This page describes company types and commercial positioning only. It makes no statement about the clinical effectiveness of any medicine or any company's programs, and it does not describe relative standing between companies.

The positions of companies change over time through acquisitions, partnerships and new program launches, so the grouping describes categories of provider and should not be read as a fixed assessment of any one firm.

Geography adds a second layer, because a provider that is strong in Europe may be small in Asia-Pacific or Latin America, and many providers use local partners to cover countries where they do not have their own regulatory and logistics presence.

Dedicated Named Patient and Managed Access Program Specialists

Dedicated specialists build their business around access programs, and for them named patient supply, managed access and early access are core services rather than one line among many.

In the report's coverage this group includes Clinigen, Inceptua Group, Tanner Pharma Group, myTomorrows, PX'Therapeutics Access Services and EVERSANA, which differ in size, service range and geographic reach.

Clinigen is described first in this group because of its long-standing focus on supplying unlicensed medicines and running managed access programs for manufacturers, with related services covering distribution, regulatory support and pharmacovigilance.

Inceptua Group and Tanner Pharma Group are covered as providers that supply medicines to patients and hospitals in countries where products are not yet authorised, and both are associated with access program management for manufacturers.

These specialists differ in the access program types they manage most often, with some focusing on named patient supply, others on manufacturer-led managed access and others on platform-based early access models.

myTomorrows is covered as a provider that connects physicians and manufacturers through a digital platform for access to medicines in development, which illustrates the growing role of technology in this part of the market.

EVERSANA is covered with its access program activity sitting within a broader commercialisation and patient services offering, which gives manufacturers a route to combine pre-launch access with later commercial support.

PX'Therapeutics Access Services is included as a provider of access-related services, and its inclusion reflects the range of company types that now take part in the market beyond the dedicated specialists.

From a manufacturer's point of view, specialists typically offer depth of regulatory knowledge, established hospital relationships in many countries and experience of the documentation each type of program needs.

Clinical Research and Development Service Providers

Clinical research and development service providers form the largest group by number of companies covered. They are organisations that primarily run clinical studies and development programs for manufacturers and that offer access programs as an extension of those services.

The report covers eight of them: ICON plc, IQVIA, Parexel, Syneos Health, Worldwide Clinical Trials, Alira Health, ClinChoice and Ergomed. They differ in size, in the therapeutic areas they emphasise and in the other services they combine with access program support.

For a manufacturer that already uses a research organisation for its development program, adding an access program can be a natural step. The provider already knows the product, the protocol and the regulatory history, which can shorten set-up.

These providers typically bring strengths in regulatory submissions, clinical operations and data management. Their teams are used to working with ethics committees and regulators, and they often have staff in many countries.

Several of the group also offer commercial, data and analytics services, so an access program can be linked to launch planning, real-world evidence collection and market access work within a single organisation.

Alira Health and Ergomed are examples of providers with a distinct profile in the group, the first combining advisory and research services in the health sector and the second combining clinical research with pharmacovigilance.

Their constraints are of focus. Access programs are one service among many, and a provider whose main business is clinical development may handle a smaller number of programs than a dedicated specialist, with a different operating model.

Manufacturers often use research organisations for programs that are closely tied to a development plan, such as expanded access or early access for an investigational product, and turn to specialists for long-running supply of products already authorised elsewhere.

Logistics, Pharmacovigilance and Compliance Service Providers

The third group supplies a single essential part of an access program rather than the whole program. It includes logistics providers, pharmacovigilance specialists and compliance and regulatory service companies.

The report covers six: Marken, PrimeVigilance, ProductLife Group, Rhenus Life Sciences, PCI Pharma Services and Catalent. Each supports a different part of the process, and manufacturers and specialists often use them as subcontractors.

Marken and Rhenus Life Sciences are covered as providers of specialised healthcare and life sciences logistics, including temperature-controlled transport, customs handling and last-mile delivery to hospitals.

Logistics capability is central because many unlicensed medicines have strict handling needs. Cold-chain integrity, documentation that travels with the shipment and the ability to clear customs quickly all affect whether a request can be fulfilled in time.

These capabilities sit behind the distribution models and end users described elsewhere, and a provider's logistics partners often define how far its network can reach.

PrimeVigilance and ProductLife Group are covered as providers of pharmacovigilance and regulatory services. Collecting and reporting safety information is a legal duty of the sponsor, and many manufacturers delegate it to specialists.

ProductLife Group also supports regulatory affairs and quality, which matter for the documentation that accompanies each shipment and for compliance with the rules in each country.

PCI Pharma Services and Catalent are covered as providers of packaging, clinical supply and manufacturing services. They support the supply of product to programs, including labelling, packaging and storage in line with regulatory requirements.

The strength of this group is depth in one function. The constraint is that none of its members runs an entire program on its own, so they usually work alongside a specialist or a research organisation.

How Company Type Relates to Manufacturer Need

The best match between a manufacturer and a provider depends on what the manufacturer lacks. A global company with strong internal regulatory teams may need only logistics, while a small developer may need the whole program run for it.

A manufacturer's development stage matters. A company with a product at the pre-approval stage may value the regulatory and clinical operations strengths of a research organisation, while one with a product authorised elsewhere may prefer a specialist with hospital relationships.

Geographic need is another factor. A program that must reach several continents requires either a provider with a wide network or a lead provider that coordinates local partners, and the reach of each company type differs.

Product handling needs also shape the choice. A cell or gene therapy needs a provider that can manage chain of identity and ultra-cold logistics, which narrows the field to those with the right infrastructure.

Buyers apply a set of selection criteria. Regulatory expertise, geographic reach, pharmacovigilance capability, supply reliability and compliance infrastructure are the five that recur, and each company type tends to be strongest on some and weaker on others.

Many manufacturers combine providers, for example by using a specialist as the lead partner, a pharmacovigilance company for safety reporting and a logistics provider for delivery in specific regions.

The commercial structure of the relationship also varies. Some programs are paid for on a service-fee basis, some are linked to the supply of product, and some combine both, and the choice influences how a manufacturer compares providers.

These considerations show why the report treats company type as the organising principle. Within each type the companies differ, but the type tells a manufacturer most about what a provider is likely to offer and where it is likely to need help.